Celldex Therapeutics

CompanyUnited StatesFounded 1983

RORWikidata

Celldex Therapeutics develops 2 assets, the furthest in phase 3 (barzolvolimab in chronic spontaneous urticaria). Mostly antibody acting on KIT and TSLP; based in the United States, founded in 1983.

2
Assets
Furthest stage
Phase 3
Raised
$64.5M
13
Trials
3
Signals

Pipeline

2
  • barzolvolimab

    Blocks KIT signaling, depleting mast cells and suppressing mast-cell-mediated inflammation.

    Phase 3, Antibody, KIT, chronic spontaneous urticaria, atopic dermatitis (Phase 2)

  • CDX-622

    Neutralizes TSLP and stem cell factor, depleting mast cells and inhibiting Type 2 inflammatory responses.

    Phase 1, Antibody, TSLP, mild-to-moderate asthma

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials21
  • Funding rounds and grants2
  • Deals5
  • People23
  • Signals7
  • Similar companies6

Intelligence